Drug Profile
ABvac 42
Alternative Names: ABvac42Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Araclon Biotech
- Class Alzheimer vaccines; Nootropics; Peptide vaccines
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for phase-I development in Alzheimer's-disease in Spain (Parenteral)
- 07 Oct 2016 ABvac 42 is still in phase I trials for Alzheimer's disease in Spain (Araclon Biotech pipeline, October 2016)
- 07 Oct 2016 Araclon Biotech plans a phase II trial for Alzheimer's disease in Spain (Araclon Biotech pipeline, October 2016)